OpenBit ResearchOpenBit
中文

What's driving Amgen (AMGN)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

TEZSPIRE Expansion Beyond Asthma

Why it matters now

Broader TEZSPIRE indications could expand product demand and revenue for Amgen.

Next checkpoint

AZN earnings (expected 2026-10-30)

This is a AZN event, linked to AMGN through a shared driver. The engine does not explain how it carries over to AMGN, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Regulatory authorities do not permit the additional indication, or subsequent commercial evidence shows no meaningful broader adoption or revenue contribution.

Research drivers

  • TEZSPIRE Expansion Beyond Asthma

    Bullish · Active · Updated

    TEZSPIRE's demonstrated efficacy in eosinophilic esophagitis supports broader indication expansion, subject to regulatory and commercial conversion.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • In the Phase 3 CROSSING trial, TEZSPIRE produced statistically significant and clinically meaningful disease and symptom improvements compared with placebo, maintained through Week 52.

    Relayed by: Benzinga · Event date on record:

  • Amgen and AstraZeneca's TEZSPIRE met both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial for eosinophilic esophagitis.

    Relayed by: Benzinga · Event date on record:

  • The efficacy of TEZSPIRE in a third epithelial-driven inflammatory disease supports its broad potential.

    Relayed by: Benzinga · Event date on record:

  • The trial's primary investigator said the 52-week CROSSING results demonstrate that tezepelumab taken every four weeks could provide a new approach to treating eosinophilic esophagitis, with the potential to help more patients ach

    Relayed by: Benzinga · Event date on record:

  • Tezspire demonstrated statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpoints at week 24, sustained through week 52 in both doses tested.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

Each row is a record as of its filing date; it does not mean the position is still held. Option records are not the same as common-stock holdings.

  • Marjorie Taylor Greene · Marjorie Greene · former House member (GA-14, left office 2026-01-05)

    PTR · Archived · Filed change: Bought · As of